Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

Conditions

Atopic Dermatitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Affiliated Hospital of China Medical University, Shenyang, China
Contact: Study coordinator (Xinghua Gao, Doctor) · gaobarry@hotmail.com · 024-83283391

Study leads

Xinghua Gao, Doctor
Study Director
First Hospital of China Medical University
Furen zhang, Doctor
Study Director
Dermatology Hospital of Shandong First Medical University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

St. Petersburg, United States

HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis

Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Hangzhou, China

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis · Atopic · Dermatitis

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Birmingham, United States

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Atopic Dermatitis (AD)

Abroad (travel likely)RecruitingPHASE2

Phoenix, United States · Phoenix, United States